How we treat Waldenström's macroglobulinemia.

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]

1994 • 6,495 citations

World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997

1999 • 3,357 citations

Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia — a new syndrome?

1944 • 658 citations

European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

2000 • 485 citations

Waldenström’s Macroglobulinemia: Clinical Features, Complications, and Management

2000 • 323 citations

Treatment of Waldenström’s Macroglobulinemia With Rituximab

2002 • 254 citations

Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenström's Macroglobulinemia, and Mantle-Cell Lymphoma

1999 • 179 citations

Immunophenotypic analysis of Waldenstrom's macroglobulinemia

2003 • 175 citations

Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil

2000 • 165 citations

Therapeutic Plasma Exchange: An Update from the Canadian Apheresis Group

1999 • 164 citations

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia

2001 • 152 citations

Fludarabine therapy in Waldenström's macroglobulinemia

1993 • 121 citations

Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity

1999 • 107 citations

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease

2001 • 100 citations

Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

2003 • 99 citations

Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.

1998 • 95 citations

Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors

1995 • 80 citations

High‐dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia

1999 • 78 citations

Fludarabine treatment in resistant Waldenstrom's macroglobulinemia

1995 • 68 citations

Plasma exchange in the long-term management of Waldenström's macroglobulinemia.

1977 • 67 citations

Cladribine (2‐CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia

1997 • 56 citations

Asymptomatic Waldenstrom's macroglobulinemia

2003 • 52 citations

Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression

2004 • 41 citations

Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia

2003 • 35 citations

Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: Review of the literature and future directions

2003 • 17 citations